47 related articles for article (PubMed ID: 15915372)
1. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.
Foureau DM; Amin A; White RL; Anderson W; Jones CP; Sarantou T; McKillop IH; Salo JC
Cancer Immunol Immunother; 2014 Dec; 63(12):1329-40. PubMed ID: 25205170
[TBL] [Abstract][Full Text] [Related]
2. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma.
Køstner AH; Ellegaard MB; Christensen IJ; Bastholt L; Schmidt H
Cancer Immunol Immunother; 2015 Mar; 64(3):349-55. PubMed ID: 25445814
[TBL] [Abstract][Full Text] [Related]
3. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.
van Bezooijen RL; Goey H; Stoter G; Hermans J; Fleuren GJ
Cancer Immunol Immunother; 1996 Dec; 43(5):293-8. PubMed ID: 9024506
[TBL] [Abstract][Full Text] [Related]
4. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD; Toole M; Merriman J; Parikh K; Daignault S; Scarlett S; Esper P; Skinner K; Udager A; Tantravahi SK; Gill D; Straubhar AM; Agarwal AM; Grossmann KF; Samlowski WE; Redman B; Agarwal N; Alva A
Cancer Immunol Immunother; 2016 Aug; 65(8):941-9. PubMed ID: 27277816
[TBL] [Abstract][Full Text] [Related]
5. Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.
Mehta K; Appleman L; Wang H; Tarhini AA; Parikh RA
PLoS One; 2016; 11(1):e0147153. PubMed ID: 26799322
[TBL] [Abstract][Full Text] [Related]
6. Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Clark JI; Curti B; Davis EJ; Kaufman H; Amin A; Alva A; Logan TF; Hauke R; Miletello GP; Vaishampayan U; Johnson DB; White RL; Wiernik PH; Dutcher JP
J Investig Med; 2021 Feb; 69(4):888-92. PubMed ID: 33542072
[TBL] [Abstract][Full Text] [Related]
7. The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma.
Pachella LA; Madsen LT; Dains JE
J Adv Pract Oncol; 2015; 6(3):212-21. PubMed ID: 26557408
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
9. The emergence of modern cancer immunotherapy.
Rosenberg SA
Ann Surg Oncol; 2005 May; 12(5):344-6. PubMed ID: 15843873
[No Abstract] [Full Text] [Related]
10. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
11. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of IL-2.
Sznol M; Parkinson DR
Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
[TBL] [Abstract][Full Text] [Related]
13. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
[TBL] [Abstract][Full Text] [Related]
14. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
15. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?
Hurst R; White DE; Heiss J; Lee DS; Rosenberg SA; Schwartzentruber DJ
J Immunother; 1999 Jul; 22(4):356-62. PubMed ID: 10404437
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
